CEPI, the Coalition for Epidemic Preparedness Innovations, is providing funding to accelerate development of vaccines targeting the Ebola Bundibugyo (BDBV) strain in response to an outbreak in eastern Democratic Republic of Congo. Multiple outlets report that CEPI will invest about $50 million to support Moderna’s investigational mRNA vaccine candidate and initial clinical testing. Other coverage says CEPI’s total package is roughly $60 million, with Moderna receiving part of the funding and two additional groups also supported. CEPI’s chief executive, Richard Hatchett, says it may be possible to prepare BDBV vaccine candidates for clinical trials within a couple of months, depending on early results. If early data are positive, funding could extend to manufacturing and advancement into later-stage studies. Reporting also notes that there are currently no approved vaccines or treatments for the Bundibugyo strain. At the same time, outlets highlight that the security situation in eastern Congo could complicate trial planning and execution, even as officials aim to “urgently accelerate” development.